Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Siu, Lillian L
  • Italiano, Antoine
  • Miller, Wilson H
  • Blay, Jean-Yves
  • Gietema, Jourik A
  • Bang, Yung-Jue
  • Mileshkin, Linda R
  • Hirte, Holger
  • Reckner, Monica
  • Higgins, Brian
  • Jukofsky, Lori
  • Blotner, Steven
  • Zhi, Jianguo
  • Middleton, Steven
  • Nichols, Gwen L
  • Chen, Lin Chi

publication date

  • May 20, 2014